NDAORALTABLET
Approved
Feb 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
FUROSEMIDE (furosemide) by Medica Corp is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1984.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Furosemide is a potent loop diuretic approved in 1984 that inhibits sodium and chloride reabsorption in the loop of Henle, proximal and distal tubules. It is indicated for heart failure, hypertension, renal impairment, and cirrhosis-related fluid overload. The drug works by blocking tubular reabsorption of electrolytes, producing rapid diuresis within 5 minutes of IV administration.
LOE Approaching
Furosemide is approaching loss of exclusivity with mature market presence; expect smaller commercial teams focused on generic competition management and brand defense.
Mechanism of Action
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption…
Worked on FUROSEMIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.